

West Virginia Medicaid Drug Utilization Review Board Minutes

May 31, 2017

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Christopher Booth, PharmD (via phone)
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
Myra Chiang, MD
Ernest Miller, DO
Michael Lonsinger, PharmD
Scott Brown, RPh
Michael Ballow, PharmD

Members Absent:

John Vanin, MD
Kate Forman, PharmD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant
Gail Goodnight, RPh, Rebate Coordinator

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, ~~Gold Health Systems~~[Change HealthCare](#)
Matthew Waldrop, PharmD, Health Information Designs (HID)
Taylor DeRuiter, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:07 p.m. EDT. The DUR Board and attendees introduced themselves.

II. APPROVAL OF MINUTES FROM March 8, 2017 DUR BOARD MEETING

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. OLD BUSINESS

- A. None

IV. NEW BUSINESS

A. **Speakers**

- 1. None

B. **Updates from the April 26, 2017 Pharmacy & Therapeutics Committee Meeting**

- 1. Dr. Labus and the Board reviewed the updates from the April 26 P&T meeting. No criteria changes were requested beyond those presented in section IV-C of this document.

C. **PDL Prior Authorization Criteria (Attachment A)**

- 1. **Cuvposa** – A motion to approve the criteria as presented was made, seconded, and passed.
- 2. **Multiple Sclerosis Agents** – A motion to approve the criteria as presented was made, seconded, and passed.
- 3. **Vivitrol** – A motion to remove the criteria was made, seconded, and passed.
- 4. **Onfi** – A motion to approve the criteria as presented was made, seconded, and passed.
- 5. **Opioid Analgesics** – A motion was made to amend the presented criteria to require prior authorization for children aged 18 years and younger for all tramadol, codeine, and long-acting agents. A motion to approve the amended criteria was made, seconded, and passed.
- 6. **Stimulants and Related Agents** – A motion to approve the criteria as presented was made, seconded, and passed.
- 7. **Hypoglycemics (DPP-4 Inhibitors, GLP-1 Agonists, SGLT2 Inhibitors, Meglitinides, Thiazolidinediones)** – the Board agreed to amend the criteria as presented to separate the class of incretin mimetics/enhancers into dipeptidyl peptidase 4 inhibitors (DPP-4) and glucagon-like peptide-1 receptor agonists (GLP-1). Prior authorization criteria wasere removed for preferred DPP-4 and meglitinide agents. Approval of non-preferred agents will require an appeal. A motion to approve the criteria as amended was made, seconded and passed.
- 8. **Hepatitis C Agents** – A motion to approve the criteria as presented was made, seconded, and passed.

V. REPORTS

- A. **Molina Quarterly Report – First Quarter 2017** – Eric Sears presented an overview of the Molina 2017 First Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.
- B. **Rational Drug Therapy Program** – Steve Small presented a review of the prior authorization program for the First Quarter 2017.

- C. Health Information Designs** – Matthew Waldrop presented an overview of the First Quarter 2017 retrospective drug utilization activity (Attachment C). The presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

- A. None

VII. NEXT MEETING AND ADJOURNMENT

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:00 p.m. EDT.
- C. The next meeting will be Wednesday, September 20, 2017 from 4:00 p.m.–6:00 p.m. and located at WVDHHR.

Submitted by:

Matthew Waldrop, PharmD, Health Information Designs